NEW YORK, NY / ACCESSWIRE / August 2, 2017 / AcelRx Pharmaceuticals saw a big drop in Tuesday trading after announcing second quarter results that failed to meet expectations. The company did, however, announce positive news about its drug candidate ZALVISO regarding a phase 3 clinical trial. Shares of Incyte Corporation also slipped after falling short with its second quarter earnings results.

RDI Initiates Coverage on:

AcelRx Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=ACRX

Incyte Corporation
https://ub.rdinvesting.com/news/?ticker=INCY

AcelRx Pharmaceuticals, Inc.'s shares closed down 12.82% on Tuesday with over 5 million shares traded compared to an average of just around 1.4 million shares. The stock slipped after the pharmaceutical company based in California reported a loss of 29 cents for the second quarter just one penny lower than the loss of 28 cents that was expected by the Street. Revenue, however, was a beat at $2.7 million compared to the $2.6 million expected by analysts. CEO Vincent J. Angotti commented, "We are making solid progress on our path to commercializing our two late-stage product candidates, DSUVIA and ZALVISO. We expect to receive a decision from the FDA on our marketing application for DSUVIA in the fourth quarter and are on track to resubmit the NDA for ZALVISO to the FDA that same quarter. We also continue to manage our expenses and cash in line with our plan leading into these major company milestones." The company expects approval of lead drug candidate DSUVIA (for the treatment of moderate-to-severe acute pain in a medically supervised setting) this year. The company also announced successful results from a Phase 3 clinical trial, IAP312, assessing ZALVISO for the management of moderate-to-severe acute pain in a hospital setting.

Access RDI's AcelRx Pharmaceuticals, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=ACRX

Incyte Corporation's shares closed down 3.40% yesterday on modest trading volume. The Delaware-based pharmaceutical company reported its second quarter results on Tuesday that fell short of what the Street was waiting for. On a per share basis, Incyte reported a loss of 6 cents. This was a penny higher than the loss of 5 cents that analysts had expected. Revenue for the period was a beat at $326.4 million compared to the $318.4 million expected. CEO Hervé Hoppenot commented, "Revenue growth from Jakafi and Iclusig continues to be very robust, driven by strong demand, and we have also made significant progress across our clinical portfolio. With strong revenue growth, a broad clinical development portfolio, comprehensive drug discovery capabilities and an expanded geographic footprint which now includes the U.S., Europe and Japan, we believe that we are well positioned for long-term value creation." Incyte's selective JAK1 inhibitor just started a phase iii trial at the beginning of last month. Shares of Incyte have seen a gain of 28% YTD and are up 42% in last one year.

Access RDI's Incyte Corporation Research Report at:
https://ub.rdinvesting.com/news/?ticker=INCY

Our Actionable Research on AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Incyte Corporation (NASDAQ: INCY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com